202 related articles for article (PubMed ID: 30580645)
1. Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study.
Fiorentini G; Sarti D; Milandri C; Dentico P; Mambrini A; Fiorentini C; Mattioli G; Casadei V; Guadagni S
Integr Cancer Ther; 2019; 18():1534735418812691. PubMed ID: 30580645
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis.
Roussakow SV
BMJ Open; 2017 Nov; 7(11):e017387. PubMed ID: 29102988
[TBL] [Abstract][Full Text] [Related]
3. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
[TBL] [Abstract][Full Text] [Related]
4. Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Trippoli S; Pelagotti F; Messori A; Vacca F; Vaiani M; Maltoni S
Drugs R D; 2003; 4(5):285-91. PubMed ID: 12952497
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas.
Quaranta M; Divella R; Daniele A; Di Tardo S; Venneri MT; Lolli I; Troccoli G
Tumori; 2007; 93(3):275-80. PubMed ID: 17679463
[TBL] [Abstract][Full Text] [Related]
7. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Carter TC; Medina-Flores R; Lawler BE
Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
[TBL] [Abstract][Full Text] [Related]
9. Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
Wang HC; Lin YT; Lin WC; Ho RW; Lin YJ; Tsai NW; Ho JT; Lu CH
World Neurosurg; 2018 Jun; 114():e766-e774. PubMed ID: 29555610
[TBL] [Abstract][Full Text] [Related]
10. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
11. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
[TBL] [Abstract][Full Text] [Related]
12. A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia.
Fiorentini G; Giovanis P; Rossi S; Dentico P; Paola R; Turrisi G; Bernardeschi P
In Vivo; 2006; 20(6A):721-4. PubMed ID: 17203754
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide and treatment of malignant glioma.
Friedman HS; Kerby T; Calvert H
Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
17. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
18. Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Parlato C; Barbarisi M; Moraci M; Moraci A
Front Biosci; 2006 May; 11():1280-3. PubMed ID: 16368514
[TBL] [Abstract][Full Text] [Related]
19. Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
Petrova L; Korfiatis P; Petr O; LaChance DH; Parney I; Buckner JC; Erickson BJ
J Neurol Sci; 2019 Oct; 405():116433. PubMed ID: 31476621
[TBL] [Abstract][Full Text] [Related]
20. Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.
Fabrini MG; Perrone F; De Franco L; Pasqualetti F; Grespi S; Vannozzi R; Cionini L
Strahlenther Onkol; 2009 Aug; 185(8):524-9. PubMed ID: 19652936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
